Efficacy and Safety of Erenumab in the Preventive and Therapeutic Treatment of Patients Suffering From Migraine
Abstract
Migraine is a prevalent and disabling neurological disorder that significantly impairs quality of life and represents a major public health concern worldwide. Erenumab, a fully human monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor, has emerged as a mechanism-based preventive therapy for migraine. This systematic review and meta-analysis evaluated the efficacy and safety of erenumab in randomized controlled trials (RCTs). Six independent RCTs involving 3,403 randomized participants were included in the quantitative synthesis. Outcome-specific denominators varied across analyses because individual trials used different efficacy and safety analysis populations and reported different outcomes. The primary outcome was the proportion of patients achieving a ≥50% reduction in monthly migraine days after 12 weeks of treatment, while secondary outcomes included changes in monthly migraine days and the incidence of adverse events. Pooled analysis demonstrated that erenumab significantly increased the likelihood of achieving a ≥50% responder rate compared with placebo (RR = 1.660, 95% CI: 1.364-2.020; p < 0.001). Erenumab also produced a significantly greater reduction in monthly migraine days compared with placebo (MD = -1.51 days/month, 95% CI: -2.03 to -0.99; p < 0.001), although substantial between-study heterogeneity was observed (I² = 76.4%). Evidence for lower-dose regimens was limited and less consistent across studies, whereas the 70-mg and…
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.